GLP-1 side effects A–Z — what does X cause?

Alphabetised side-effect entries

Each entry describes the current evidence base, the likely mechanism where known, and provides a cross-link to the dedicated safety-signal page where one exists. Entries for symptoms without a dedicated page follow the same evidence-led framing.

Acid reflux / heartburn

Gastro-oesophageal reflux symptoms are a recognised gastrointestinal signal in the incretin class, consistent with the delayed gastric emptying that is an on-target pharmacological effect. Reports are most frequent during dose titration and tend to diminish at maintenance dose. In pivotal trials, reflux was categorised as a mild-to-moderate GI event. Reported in pharmacovigilance signals; not a primary class-effect concern beyond the GI category. Persistent or severe symptoms warrant qualified clinical review. See: GLP-1 gastrointestinal adverse events.

Bloating

Abdominal bloating and distension are reported as part of the broader gastrointestinal adverse event profile common to the incretin class. Delayed gastric emptying is the principal proposed mechanism. Bloating is generally transient, most common during titration, and less frequently reported at stable maintenance doses in long-term trial data. Reported in pharmacovigilance signals; not a primary class-effect concern in pivotal trials. Persistent or severe symptoms warrant qualified clinical review. See: GLP-1 gastrointestinal adverse events.

Constipation

Constipation is one of the most consistently reported GI adverse events across both semaglutide and tirzepatide pivotal programmes, reflecting reduced gut motility secondary to GLP-1 receptor activation. In SURMOUNT-1, constipation was reported in a meaningful proportion of tirzepatide participants, particularly at higher doses. Adequate hydration and dietary fibre intake are commonly recommended supportive measures. Persistent or severe constipation warrants clinical review to exclude other causes. See: GLP-1 gastrointestinal adverse events.

Depression / mood changes

Mood changes and psychiatric signals in GLP-1 pharmacovigilance are the subject of ongoing regulatory review. The MHRA and EMA have both indicated they are monitoring signals including depression, anxiety and suicidal ideation. Available trial-level data do not establish a causal link, but the signal warranted formal assessment. Clinical judgement and monitoring remain important, particularly in individuals with a history of mood disorder. See: Psychiatric adverse event signal tracking.

Diabetic retinopathy / vision changes

An increased risk of diabetic retinopathy complications was observed in SUSTAIN-6 (semaglutide vs placebo in type 2 diabetes), and has been the subject of EMA and MHRA regulatory attention. The proposed mechanism involves rapid HbA1c reduction in individuals with pre-existing retinopathy rather than a direct drug effect on the retina. The signal is most relevant in people with established diabetic retinopathy starting incretin therapy. See: Diabetic retinopathy and rapid HbA1c reduction.

Diarrhoea

Diarrhoea is a primary GI adverse event across the incretin class and is among the most common reasons for early discontinuation in pivotal trials. It is dose-dependent and most frequent during titration. In both STEP and SURMOUNT trial programmes, diarrhoea was classified as mild-to-moderate in the majority of cases, with severe diarrhoea reported in a small minority. Dehydration risk is clinically relevant, particularly in older adults or those on concurrent diuretics. See: GLP-1 gastrointestinal adverse events.

Fatigue

Fatigue is reported across GLP-1 trial programmes but is considered multifactorial: reduced caloric intake, altered sleep patterns associated with weight change, and possible direct effects on energy regulation may all contribute. Fatigue is not identified as a primary class-effect pharmacological signal in the way GI events are. It is common during initiation and typically resolves. Reported in pharmacovigilance signals; not a primary class-effect concern in pivotal trials. Persistent or severe fatigue warrants qualified clinical review to exclude other causes.

Gallbladder problems / cholelithiasis

Gallstone formation (cholelithiasis) and related biliary events are an established safety signal for GLP-1 therapies, linked to rapid weight loss rather than a direct drug effect on biliary physiology — though the mechanisms are not fully elucidated. The risk is proportionate to the degree and rate of weight loss. Regulatory agencies have required labelling of this risk. See: Gallbladder disease and rapid weight loss.

Hair loss / hair thinning

Hair thinning and loss (alopecia) have been reported in GLP-1 pharmacovigilance signals, particularly in the context of significant rapid weight loss. The proposed mechanism is telogen effluvium — a form of stress-related hair shedding triggered by metabolic perturbation, nutritional deficits (particularly protein and micronutrients) and rapid caloric restriction, rather than a direct pharmacological effect of the medicine itself. Hair loss is not listed as a primary class-effect concern in pivotal trial safety tables. Adequate protein intake is routinely recommended during significant weight loss. Persistent or severe hair loss warrants qualified clinical review.

Headache

Headache is a commonly reported adverse event during initiation of GLP-1 therapy. The mechanism is not fully characterised but may relate to altered gastrointestinal transit, changes in caloric intake, hydration status or direct central effects of GLP-1 receptor activation. In pivotal trials, headache was generally classified as transient and mild. Reported in pharmacovigilance signals; not a primary class-effect concern in pivotal trials. Persistent, severe or unusual headaches warrant qualified clinical review.

Hypoglycaemia

Hypoglycaemia is not a primary safety signal of GLP-1 receptor agonist monotherapy in non-diabetic populations because the glucose-lowering mechanism is glucose-dependent (insulin secretion is stimulated only when blood glucose is elevated). However, the risk is clinically significant when GLP-1 medicines are used concurrently with insulin or sulfonylureas, where dose adjustment of the insulin or sulfonylurea may be required. See: Hypoglycaemia risk by drug class.

Injection-site reactions

Local injection-site reactions — including erythema, bruising, pruritus and nodule formation — are reported with all subcutaneous incretin agonists. Rates in clinical trials are generally low and reactions are typically mild and transient. Correct injection technique, site rotation and storage of the device at the recommended temperature are important mitigation factors. See: Injection-site reactions in clinical trials.

Muscle loss / lean mass concerns

Loss of lean (muscle) mass during significant caloric restriction is a general nutritional risk, not unique to GLP-1 therapy. Trial data show that a proportion of weight lost on GLP-1 and dual agonist therapy includes lean mass alongside fat mass. Adequate dietary protein, resistance exercise and clinical monitoring are the primary mitigation strategies identified in nutritional literature. See: Lean mass and nutritional risk.

Nausea / vomiting

Nausea is the most frequently reported adverse event in GLP-1 pivotal trial programmes and is the dominant tolerability driver — it is the primary reason for early discontinuation in a minority of participants. Nausea reflects the on-target GI effects of incretin receptor activation (particularly delayed gastric emptying and central appetite suppression). In STEP-1, nausea was reported in approximately one-third of semaglutide participants, predominantly during titration. Dose-escalation protocols are designed specifically to manage this. See: GLP-1 gastrointestinal adverse events.

Pancreatitis

Acute pancreatitis has been identified as a pharmacovigilance signal for the incretin class and is included in regulatory labelling as a risk to monitor for. Absolute rates in pivotal trials are low and a definitive causal relationship has not been established. Any new-onset upper abdominal pain — particularly radiating to the back — in a person on incretin therapy requires urgent clinical assessment, not self-management. See: Pancreatitis signal.

Suicidality / psychiatric adverse events

Regulatory agencies including the EMA and MHRA have formally assessed a pharmacovigilance signal linking GLP-1 receptor agonists to suicidal ideation and self-harm. Available data do not establish a causal relationship, but the signal warranted regulatory review. Both the EMA and MHRA have published their conclusions and continue to monitor emerging data. Any concerns about mood, suicidal thoughts or self-harm require immediate clinical or emergency support — not a reference website. See: Psychiatric adverse event signal tracking.

Thyroid concerns / C-cell warning

GLP-1 receptor agonists carry a class warning relating to thyroid C-cell tumours, based on animal study findings (rodent carcinogenicity data). The applicability to humans is uncertain; however, these medicines are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This warning applies to all licensed GLP-1 receptor agonists. See: Thyroid C-cell warning explained.

Frequently asked questions

Should I stop my medicine if I experience side effects?

You should not stop or alter your dose without consulting your prescribing clinician. Many side effects — particularly gastrointestinal — are dose-dependent and resolve during titration. Abrupt discontinuation carries its own risks. Your prescriber can advise on dose adjustment, timing, or whether to pause therapy.

How long do GLP-1 side effects usually last?

Gastrointestinal side effects are most common during dose escalation and typically improve or resolve once a maintenance dose is established. Timing varies between individuals and between medicines. STEP and SURMOUNT trial data suggest most participants' GI events were mild-to-moderate and transient.

Where do I report a suspected adverse drug reaction in the UK?

Report via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Reports from patients and carers are accepted directly and contribute to post-marketing pharmacovigilance signals.

Are side effects worse at higher doses?

Dose-dependent GI tolerability is a recognised feature of the incretin class. Pivotal trials consistently show higher rates of nausea, vomiting and diarrhoea at higher dose levels, which is why slow titration protocols are part of the prescribing strategy.

Can taking the injection with food reduce nausea?

This is a common practical suggestion and is supported by clinical experience in prescribing guidance, though evidence from controlled trials specifically testing meal timing is limited. Your prescriber or pharmacist is the right source for individual administration advice.

Is one GLP-1 medicine better tolerated than another?

Tolerability profiles differ between semaglutide and tirzepatide, and between subcutaneous and oral formulations, but head-to-head tolerability data are limited. Observed differences in trial populations may reflect dose titration protocols, formulation differences and population selection rather than intrinsic pharmacological differences.

Do side effects become less common over time on GLP-1 therapy?

Long-term extension data and open-label extension arms of the STEP and SURMOUNT programmes suggest GI adverse event rates decline markedly after initial titration, with most participants in long-term follow-up experiencing far fewer GI events than during dose escalation.

What is the MHRA Yellow Card scheme?

The Yellow Card scheme is the UK's pharmacovigilance system, operated by the MHRA, for collecting reports of suspected side effects and safety concerns about medicines, vaccines and medical devices. It is open to healthcare professionals, patients and carers.

Can I take over-the-counter medicines for GLP-1 side effects?

This is a clinical question for your prescriber or pharmacist, who can advise on which OTC remedies (antiemetics, laxatives, antacids) are appropriate given your full medication list and health status. This page does not provide personal medication guidance.

Are all GLP-1 side effects listed in the summary of product characteristics?

The Summary of Product Characteristics (SmPC) for each licensed product lists adverse reactions identified in clinical trials and post-marketing. SmPCs are publicly available via the MHRA's Product Information website. Pharmacovigilance signals may extend beyond what is listed at the time of initial approval.

Is hair loss permanent after starting a GLP-1 medicine?

Based on available pharmacovigilance signals and the proposed mechanism (rapid-weight-loss-related telogen effluvium), hair thinning is generally considered a transient finding. It is not listed as a primary class-effect concern in pivotal trials. Persistent or severe hair loss warrants assessment by a clinician.